![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 27, 2009 3:10:55 PM
I think I understand the sentiment expressed. I just strongly fail to see how the ability to dilute yourself to 200 million shares, regardless of the terms, at nickel a share(or dime)or even 20 cents, shows/means the company's back is not completely against the wall.
True the company would have to wind down after the shareholder meeting. The question is this: would a sale of the company provide a more painless way for existing shareholders, even providing a small to medium sized premium over 20 cents than diluting the company down under 10 cents for providing that extra six months of "shelf life" so the company can provide suitors they have a bit more time.
To somebody who really wants to partner with Cortex(the type of company who should ink a deal in the next 30-45 days) perhaps, just perhaps, extending the cash cushion by six more months might lead them to finish the lawyer checks, rounding up the CFO's signature, whatever. But, even then I do not think it is worth it.
The simple truth is Cortex 'is' out of options, or should be. If Cortex cannot pull a subpar deal out of the hat by the shareholder meeting, what would another six months of cash provide? Now, if one needed to wait for some earth shattering ADHD clinical results, ok, then waiting and gambling might be worth it, but I do not believe Varney is offering anything that warrants authorizing additional shares.
I hope to be proved wrong. I hope a deal to allow Cortex to move forward, developing their technology, perhaps two can be inked in the next three weeks. I hope that some surprising results come out in sleep apnea, showing great viability and this might make it 'worth' diluting the company, raising money to allow a fine sleep apnea deal. But without any production by management, sell the company makes the most sense to me.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM